Arcus Biosciences (NYSE:RCUS) President Sells $221,223.28 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 9,983 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total transaction of $221,223.28. Following the transaction, the president directly owned 346,012 shares of the company’s stock, valued at $7,667,625.92. The trade was a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Arcus Biosciences Trading Down 1.2%

NYSE:RCUS traded down $0.26 during mid-day trading on Thursday, hitting $22.02. The company had a trading volume of 1,175,874 shares, compared to its average volume of 1,200,446. The business’s fifty day moving average is $20.82 and its two-hundred day moving average is $13.98. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The firm has a market cap of $2.38 billion, a P/E ratio of -6.40 and a beta of 0.75. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $26.40.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. During the same quarter last year, the firm posted ($1.00) EPS. Arcus Biosciences’s revenue was down 45.8% compared to the same quarter last year. As a group, research analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC increased its stake in Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after buying an additional 1,021 shares during the period. SBI Securities Co. Ltd. raised its position in Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after acquiring an additional 2,845 shares in the last quarter. CWM LLC lifted its stake in shares of Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after buying an additional 3,810 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after acquiring an additional 1,796 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Arcus Biosciences by 440.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after acquiring an additional 6,191 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

RCUS has been the subject of several research analyst reports. Wedbush set a $35.00 target price on shares of Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Bank of America lifted their price objective on shares of Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research note on Friday, November 28th. Finally, Wall Street Zen upgraded shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.